21-day comprehensive spa care for kidney and urinary conditions
Official title: Objective Assessment of the Effect of Comprehensive Spa Care on Patients With Chronic Kidney and Urological Diseases: A Prospective Interventional Clinical Study
Run by Institute of Spa and Balneology, public research institution · NCT07435844 · Data updated 2026-11-12
This program will try a 21-day spa treatment with mineral water baths, drinking cures, exercise and diet for adults 40–70 who have chronic kidney or urinary problems to see if it improves symptoms and kidney health.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 40 Years to 70 Years |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Institute of Spa and Balneology, public research institution Academic / other |
| Locations | 1 site (Mariánské Lázně, Carlsbad Region) |
| Status | Recruiting |
| Started | April 7, 2026 |
| Main results expected | April 30, 2027 |
| Study ends | April 30, 2027 |
| Registry record updated | April 24, 2026 |
| Trial ID | NCT07435844 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 40–70 who are prescribed the KLP for recurrent or chronic non-tuberculous kidney/urinary inflammation, nephrolithiasis/nephrocalcinosis, post‑surgical recovery of the urinary tract, or chronic prostatitis are ideal candidates.
✕Probably not a fit
Patients with acute urinary obstruction or other acute surgical needs, severe comorbidities, inability to walk to treatments, or those outside the 40–70 age range may not receive benefit from this spa program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, single-arm pretest–posttest study of 150 adults receiving a standard 21-day comprehensive spa care program (KLP) at Mariánské Lázně. Participants receive a prescribed package of local natural therapies including mineral spring drinking cures, mineral water baths, peloid applications, carbon dioxide therapy, climatotherapy, exercise therapy and dietotherapy, totaling about 63 procedures. Clinical data, blood and urine samples, and other measures are collected no later than day 3 after admission and again on day 20 or 21 to compare before-and-after effects. The treatments are provided as routine, insurance-covered care and the protocol does not alter individual clinical prescriptions.
Why it matters
Potential benefit: If successful, the program could reduce urinary symptoms and inflammation and improve kidney-related health and quality of life after a 21-day course.
How similar studies have gone: Previous observational and non-randomized reports of balneotherapy and spa rehabilitation have shown symptom improvements in some urologic and nephrologic conditions, but high-quality randomized evidence remains limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female aged 40 to 70 years * Prescribed comprehensive spa care (KLP) for one of the following indications: recurrent and chronic non-tuberculous inflammation of the kidneys and urinary tract resistant to antibiotic and pharmacological treatment, with at least 12 months of continuous urological care (indication VIII/1); cystic kidney disease (indication VIII/1); nephrolithiasis without urinary tract obstruction or nephrocalcinosis (indication VIII/2); conditions after kidney or urinary tract surgery, including endovesical procedures, complicated prostatectomy, nephrolithotripsy, or recovery after extracorporeal shock wave lithotripsy (indication VIII/3); chronic prostatitis or chronic prostatovesiculitis resistant to pharmacological and antibiotic treatment, with at least 12 months of continuous urological care (indication VIII/4) * Able to walk from the sanatorium to the colonnade and back three times daily * Willing to follow the treatment plan * Signed informed consent Exclusion Criteria: * Contraindications according to Czech Decree No. 2/2015 Coll. on spa treatment criteria (pregnancy, acute illness, etc.) * Significant mobility limitation or severe neuropathy preventing daily walks to the colonnade * Significant obesity or inability to briefly hold breath (required for ultrasound examination) * Alcohol intake exceeding 20 g of ethanol per day * Nephrolithiasis with urinary tract obstruction * History of esophageal or gastric variceal bleeding * Severe comorbidities that could affect treatment outcomes * Active oncological disease * Unwillingness to adhere to the treatment plan
Where it's running
-
Léčebné lázně Mariánské Lázně a.s.
Mariánské Lázně, Carlsbad Region, Czechia Recruiting
Study contacts
- Study coordinator: Ondřej Vacek, Mgr.
- Email: vacek@i-lab.cz
- Phone: +420 603 934 414
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using vorolanib for treating advanced kidney cancer
This study is testing if the drug vorolanib can help people with advanced kidney cancer live longer when used as a second treatment option.
-
Suction vs Conventional Ureteral Access Sheaths in Kidney Stone Surgery
This study tests whether using a suction ureteral access sheath during RIRS helps adults clear stones more often and potentially reduces operative time and infections compared with a conventional sheath.
-
Observation vs Upfront Surgery for Asymptomatic Kidney Stones in Children and Adults
This trial tests whether watching asymptomatic kidney stones or performing upfront surgery is better for reducing life disruption in patients aged 6 and older.
-
Tract Closure with Hemostatic Agent in PCNL
This trial tests whether applying a hemostatic agent during tract closure in PCNL helps reduce blood loss compared with balloon tamponade alone.
-
Gentamicin Irrigation and Suction Ureteral Access in Kidney Stone Surgery
This trial tests whether using gentamicin-containing irrigation fluid and a suction-enabled ureteral access sheath during retrograde intrarenal surgery (RIRS) can lower fever, SIRS, and sepsis after kidney stone treatment.
-
Gepotidacin in Breast Milk of Healthy Lactating Women
This study will test how gepotidacin behaves in the breast milk of healthy lactating women who are breastfeeding.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.